Pulike Biological Engineering (603566) - Total Assets
Based on the latest financial reports, Pulike Biological Engineering (603566) holds total assets worth CN¥3.09 Billion CNY (≈ $452.33 Million USD) as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore Pulike Biological Engineering debt service capacity to assess how comfortably operating cash covers total debt obligations.
Pulike Biological Engineering - Total Assets Trend (2009–2024)
This chart illustrates how Pulike Biological Engineering's total assets have evolved over time, based on quarterly financial data. See Pulike Biological Engineering book value and equity for net asset value and shareholders' equity analysis.
Pulike Biological Engineering - Asset Composition Analysis
Current Asset Composition (December 2024)
Pulike Biological Engineering's total assets of CN¥3.09 Billion consist of 40.9% current assets and 59.1% non-current assets.
| Asset Category | Amount (CNY) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 6.6% |
| Accounts Receivable | CN¥379.04 Million | 12.2% |
| Inventory | CN¥192.60 Million | 6.2% |
| Property, Plant & Equipment | CN¥0.00 | 0.0% |
| Intangible Assets | CN¥279.18 Million | 9.0% |
| Goodwill | CN¥17.81 Million | 0.6% |
Asset Composition Trend (2009–2024)
This chart illustrates how Pulike Biological Engineering's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see 603566 stock market capitalisation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Pulike Biological Engineering's current assets represent 40.9% of total assets in 2024, a decrease from 54.6% in 2009.
- Cash Position: Cash and equivalents constituted 6.6% of total assets in 2024, down from 31.9% in 2009.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 9.0% of total assets, an increase from 6.0% in 2009.
- Asset Diversification: The largest asset category is accounts receivable at 12.2% of total assets.
Pulike Biological Engineering Competitors by Total Assets
Key competitors of Pulike Biological Engineering based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Klotho Neurosciences, Inc.
NASDAQ:KLTO
|
USA | $10.07 Million |
|
Aktis Oncology, Inc. Common stock
NASDAQ:AKTS
|
USA | $279.04 Million |
|
Neurotech International Ltd
AU:NTI
|
Australia | AU$6.81 Million |
|
Jazz Pharmaceuticals plc
F:J7Z
|
Germany | €11.86 Billion |
|
Uniqure NV
NASDAQ:QURE
|
USA | $888.38 Million |
|
Brainstorm Cell Therapeutics Inc
NASDAQ:BCLI
|
USA | $571.00K |
|
Kura Oncology Inc
NASDAQ:KURA
|
USA | $652.55 Million |
|
Bioventix
LSE:BVXP
|
UK | GBX13.03 Million |
Pulike Biological Engineering - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.89 | 2.93 | 3.04 |
| Quick Ratio | 2.51 | 2.51 | 2.58 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CN¥869.96 Million | CN¥795.80 Million | CN¥589.94 Million |
Pulike Biological Engineering - Advanced Valuation Insights
This section examines the relationship between Pulike Biological Engineering's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.79 |
| Latest Market Cap to Assets Ratio | 0.17 |
| Asset Growth Rate (YoY) | -5.1% |
| Total Assets | CN¥3.10 Billion |
| Market Capitalization | $521.08 Million USD |
Valuation Analysis
Below Book Valuation: The market values Pulike Biological Engineering's assets below their book value (0.17x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Pulike Biological Engineering's assets decreased by 5.1% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Pulike Biological Engineering (2009–2024)
The table below shows the annual total assets of Pulike Biological Engineering from 2009 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥3.10 Billion ≈ $453.22 Million |
-5.06% |
| 2023-12-31 | CN¥3.26 Billion ≈ $477.36 Million |
-3.67% |
| 2022-12-31 | CN¥3.39 Billion ≈ $495.56 Million |
+56.19% |
| 2021-12-31 | CN¥2.17 Billion ≈ $317.29 Million |
+6.87% |
| 2020-12-31 | CN¥2.03 Billion ≈ $296.88 Million |
+6.47% |
| 2019-12-31 | CN¥1.91 Billion ≈ $278.83 Million |
+0.13% |
| 2018-12-31 | CN¥1.90 Billion ≈ $278.48 Million |
+5.43% |
| 2017-12-31 | CN¥1.81 Billion ≈ $264.14 Million |
+3.93% |
| 2016-12-31 | CN¥1.74 Billion ≈ $254.15 Million |
+15.50% |
| 2015-12-31 | CN¥1.50 Billion ≈ $220.04 Million |
+79.50% |
| 2014-12-31 | CN¥837.72 Million ≈ $122.59 Million |
+14.65% |
| 2013-12-31 | CN¥730.68 Million ≈ $106.92 Million |
+25.52% |
| 2012-12-31 | CN¥582.13 Million ≈ $85.18 Million |
+16.30% |
| 2011-12-31 | CN¥500.56 Million ≈ $73.25 Million |
+13.37% |
| 2010-12-31 | CN¥441.53 Million ≈ $64.61 Million |
+35.33% |
| 2009-12-31 | CN¥326.26 Million ≈ $47.74 Million |
-- |
About Pulike Biological Engineering
Pulike Biological Engineering, Inc. engages in the research, development, production, and sale of veterinary biological products, chemical drugs, and traditional Chinese veterinary drugs. The company offers vaccines, antibodies, and medicines for swine and poultry, as well as disinfectants. Pulike Biological Engineering, Inc. was founded in 1995 and is headquartered in Luoyang, China.